Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Jonathan Leiken has been appointed Senior Vice President and General Counsel, effective ...

Danaher Corporation (NYSE:DHR) is one of the best strong buy healthcare stocks to buy now. On July 23, UBS lowered the firm’s ...

Danaher Corporation (NYSE:DHR) is a stock that Jim Cramer has a bittersweet relationship with. His trust has continued to ...

Danaher Corporation (NYSE:DHR) is one of the stocks Jim Cramer shed light on. While discussing the stock’s condition over the past couple of years, Cramer showed a positive sentiment toward the stock, ...

Danaher Corporation thrives on bioprocessing demand and diagnostics resilience. Click for why, with solid execution and 80% ...

Q2 2025 Earnings Call Transcript July 22, 2025 Danaher Corporation beats earnings expectations. Reported EPS is $1.8, ...

--Danaher Corporation announced today that it has completed the separation of its Environmental& Applied Solutions segment, through the spin-off of Veralto Corporation. Veralto will begin "regular ...

Danaher's third quarter Compared to last year's third quarter, overall revenue increased 6.5%, comprising core revenue growth of 3% and contributions from acquisitions of 10.5%.

Summary Danaher Corporation incorporates science and technology and has a market cap of $150B. The company has mixed financials, with its gross profit margin being its strongest and most consistent.

About a year ago, Danaher Corporation 's (NYSE: DHR) valuation looked cheap relative to its peers. Of course, when I write peers, I mean its medical, life sciences, and diagnostics peers because ...

Danaher Corporation (NYSE:DHR) last week reported its latest full-year results, which makes it a good time for investors to dive in and see if the business is performing in line with expectations ...